menu
    • menu
    [{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Benzgalantamine gluconate","moa":"ACHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Titan Partners Group","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Titan Partners Group"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Benzgalantamine gluconate","moa":"ACHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Titan Partners Group","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Titan Partners Group"}]

    Find Clinical Drug Pipeline Developments & Deals for Benzgalantamine gluconate

    Menu

    Benzgalantamine gluconate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alpha Cognition

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzgalantamine gluconate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Titan Partners Group

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering

                            Details : The Company plans to allocate the net proceeds for the acceleration of commercial launch of Zunveyl (benzgalantamine), a prodrug of galantamine, an acetylcholinesterase inhibitor.

                            Product Name : Zunveyl

                            Product Type : Miscellaneous

                            Upfront Cash : $35.0 million

                            September 30, 2025

                            Lead Product(s) : Benzgalantamine gluconate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Titan Partners Group

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alpha Cognition

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzgalantamine gluconate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Titan Partners Group

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

                            Details : The Company plans to allocate the net proceeds for the acceleration of commercial launch of Zunveyl (benzgalantamine), a prodrug of galantamine, an acetylcholinesterase inhibitor.

                            Product Name : Zunveyl

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 30, 2025

                            Lead Product(s) : Benzgalantamine gluconate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Titan Partners Group

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth